Advanced Tactile Imaging, Inc.

We are driven to provide new and innovative ways of diagnosing and treating health conditions that affect women everywhere. We are simultaneously developing two cutting-edge diagnostic platforms by collaborating with world-renowned physicians and researchers. We believe that an objective understanding of facts is crucial to develop the best technologies. We believe that thoughts must be openly considered and scrutinized to advance our ability to bring technology that is clinically useful to the market which can improve patient outcomes. We believe that we must strive to follow the best ideas and remain agnostic to the stage of development. We believe that the only way to ensure rigorous scientific inquiry is with a strong foundation of support and respect. Our pipeline consists of technologies developed by leading researchers in their fields. Preterm birth is a major global health problem.

Our products have been deployed in more than 8 countries to date on more than 1000 patients. Our vision is to sustainably improve access to women’s cancer prevention with a low-cost, hand-held, portable imaging devices, mHealth communication platforms, and an automated decision-making algorithm. Our vision is to sustainably improve access to women’s cancer prevention with a low-cost, hand-held, portable imaging devices. Not only did these diverse group of partners help to inform product development through the human centered design process, but these very stakeholders have demonstrated that our robust technologies can be used in a wide variety of settings and by gynecologists, obstetricians, nurses, midwives and medical officers. Our latest product launch, The Pocket Colposcope, received FDA clearance in September 2018. Opt-in to receive the latest updates on Calla Health Technology products, research, and innovations. Calla Health is a newly formed entity dedicated to improving the lives of women through technological innovations. The key innovation that will help us achieve our goal is a product called the Pocket Colposcope, which was created as a result of a 3-year human centered design process between Duke , 3rd Stone Design and clinical partners in the U.S., Peru, Tanzania, Zambia and Kenya.

We are excited to move forward as a leader in cervical cancer diagnostics, evolving into a global leader in the world of FemTech. The Eva Pro mini colposcope provides a superior image quality combining with an advanced software capability, powered by AI and tele health. The ThermoGlide offers immediate point-of-care treatment with minimal discomfort and downtime.

We are still in the process of making this device and want to better understand our customers and their needs. We are currently in the process of gaining medical device certification as a Class IIa device according to the European Medical Device Regulation (MDR), which includes rigorous safety testing and clinical trials. In the meantime, we are working towards setting up clinical trials. Ella has since set out to forge a novel and innovative treatment for vaginal infections and accelerate advances in women’s healthcare.Since starting Uvisa, Ella, along with the rest of the team, have won several competitions and awards of recognition within both the Danish entrepreneurship ecosystem and further afield. This a MedTech company that built the world’s first automated blood sampling device. By providing this reusable home-treatment we aim to provide a discrete and cost effective solution to relieve the symptoms of common vaginal infections. Prescription and over-the-counter medications currently serve as the sole solutions. It offers an alternative to pharmacological solutions and transforms how women deal with vaginal infections.

The Company utilized this technology as the baseline and further developed innovative image processing algorithms for enhancing subtle lesions in digital mammograms as its first product and enhancing abnormalities in general radiology images. AIE aims to provide physicians with every possible advantage in the screening and diagnosis of breast cancer and other anatomical diseases. Initial product launch in QTR4 2009 with Hologic.

The company has advanced patented infrared sensor technology to the stage of pilot production.